Skip to main content
Clinical Trials/NCT04731012
NCT04731012
Recruiting
Not Applicable

Immunological and Cardiovascular Phenotyping of Oocyte-donation Pregnancies

Charite University, Berlin, Germany1 site in 1 country1,000 target enrollmentJanuary 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Preeclampsia
Sponsor
Charite University, Berlin, Germany
Enrollment
1000
Locations
1
Primary Endpoint
Preeclampsia in oocyte-donation pregnancies is caused by an altered composition of immune cells in placenta and blood.
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

The investigators conduct a study to evaluate the underlying causes of preeclampsia in oocyte-donation pregnancies.

Detailed Description

A detailed medical history, questionnaires as well as blood, urine and placental samples will be used to analyse several factors leading to the high risk of preeclampsia in oocyte-donation pregnancies.

Registry
clinicaltrials.gov
Start Date
January 1, 2020
End Date
December 1, 2025
Last Updated
5 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Florian Herse

Doctor of Science

Charite University, Berlin, Germany

Eligibility Criteria

Inclusion Criteria

  • pregnancy

Exclusion Criteria

  • severe auto immune disorders

Outcomes

Primary Outcomes

Preeclampsia in oocyte-donation pregnancies is caused by an altered composition of immune cells in placenta and blood.

Time Frame: 01.01.2020 - 01.12.2025

T-Cell populations are altered in preeclampsia. HLA-mismatch of mother and donor oocyte lead to a "host-versus-graft" reaction. T-, B- and Natural killer cells are altered in placental tissue of oocyte-donation pregnancies.

Secondary Outcomes

  • Preeclampsia in oocyte-donation pregnancies is caused by an activation of pro-inflammatory factors and endothelial dysfunction.(01.01.2020 - 01.12.2025)

Study Sites (1)

Loading locations...

Similar Trials